Kyorin Pharmaceutical Co Ltd
KYORIN Pharmaceutical Co., Ltd., through its subsidiaries, researches and develops, manufactures, and sells ethical and generic drugs in Japan and internationally. The company offers Flutiform, a drug for the treatment of asthma; Lyfuna for cough treatment; Desalex, an antiallergic agent; Beova, and Uritos KYORIN therapeutic agents for overactive bladder; Lasvic, a quinolone synthetic antibacterial agent; Pentasa, a remedy for ulcerative colitis/Crohn's disease; Nasonex and Mometasone KYORIN, which are used as allergic rhinitis therapeutic agents; and Kipres, a leukotriene receptor antagonist anti-bronchial asthma and allergic rhinitis drug. It also provides Mucodyne, a mucoregulating drug; GeneSoC, a real-time PCR system; Rubysta, a disinfectant cleaner; Milton, a disinfectant; over-the-counter drugs; and prescription medicines and quasi-drugs, and diagnostics business. In addition, the company offers subcontracted drug manufacturing services. It has development and commercialization agreement with Hyfe Inc. for digital therapeutics (DTx) for chronic cough. The company was formerly known as KYORIN Holdings, Inc. KYORIN Pharmaceutical Co., Ltd. was founded in 1923 and is headquartered in Tokyo, Japan.
If you'd bought from year…
Same habit, different start year. Each row shows what a constant habit's worth of 4569-T would be worth today, had you started buying at that point in the asset's history.
| Started | $6/day$6/day coffee | $42/wk$42/week coffee |
|---|---|---|
| Year 1 (2001) — listing | $41,009 1.1× | $59,991 1.1× |
| Year 6 (2006) | $31,247 1.0× | $46,324 1.0× |
| Year 11 (2011) | $19,533 0.9× | $29,005 0.9× |
| Year 16 (2016) | $12,203 0.8× | $18,075 0.8× |
| Year 21 (2021) | $6,530 0.8× | $9,759 0.8× |
Repeated investment, no fees, dividends reinvested. $6/day coffee = $180 / month equivalent.
Popular scenarios with 4569
For illustration only — not investment advice. Past performance is not indicative of future results.